Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study
References (40)
- et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
J Am Coil Cardiol
(2004) - et al.
Serum triglycerides in the prediction of coronary artery disease (an Italian experience)
Am J Cardiol
(1994) New insight into the pathophysiology of lipid abnormalities in type 2 diabetes
Diabetes Metab
(2005)Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (45)
Lancet
(1994)- et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
N EnglJ Med
(1995) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial
Lancet
(2002)- et al.
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data From 90,056 participants in 14 randomised trials ofstatins [published correction appears in Lancet. 2005;366:1358]
Lancet
(2005) - et al.
Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options
Am J Cardiol
(2005) - et al.
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
Circulation
(1989) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation
(2002)
Targeting low high-density lipoprotein cholesterol for therapy: Lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial
Am J Cardiol
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment
Eur Heart J
Therapeutic management of dyslipidemic patients: Guidelines [in French].
European guide-lines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)
Eur J Cardiovasc Prey Rehabil
Plasma triglyceride level and mortality from coronary heart disease
N Engl J Med
Do triglycerides provide meaningful information about heart disease risk?
Arch Intern Med
Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study [published correction appears in Circulation. 1998; 97:1995]
Circulation
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
J Cardiovasc Risk
Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speed-well Collaborative Heart Disease Studies
Br Heart J
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
JAMA
Cited by (29)
Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients
2016, AtherosclerosisCitation Excerpt :Overall, only approximately a quarter (26.8%) of patients attained their target LDL-C level, despite chronic statin therapy. Other studies have also reported poor target achievement for patients receiving statin treatment [12–15]. However, the numbers cannot be directly compared to those of DYSIS owing to differences in the study populations, targets used, and methodology of acquisition.
Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception
2014, Clinica e Investigacion en ArteriosclerosisCitation Excerpt :Additionally, we found a high prevalence of poor control of LDL-C. Only 8.8% of patients had achieved the recommended targets. Several studies showed similar target achievement rates for this lipoprotein,18,22–24 and a worse control in patients with higher cardiovascular risk.18 Thus, our results corroborated that a high proportion of patients do not meet target levels of LDL-C, particularly in high-risk cases, even though therapy for AD is directed to first lowering serum LDL-C levels.
Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada
2013, European Journal of Internal MedicineCitation Excerpt :On the other hand, more than a third of high-risk patients continued to have low HDL-C, and over 40% of patients still had low HDL-C and/or elevated triglycerides despite lipid modifying treatment. The results of this longitudinal study are largely consistent with those of cross-sectional studies, which analyzed normal lipid level attainment among patients who did and did not receive lipid modifying treatment [19–21]. Although these studies found a high prevalence of multiple lipid abnormalities ranging from 30 to 40%, the cross-sectional design made it difficult to determine the extent to which LMT was associated with changes in lipid profiles among the patients studied.
Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia
2013, Clinical TherapeuticsCitation Excerpt :A longitudinal study using data from a US health maintenance organization reported that LMT use significantly improved LDL-C goal attainment; however, nearly 50% of patients did not achieve normal HDL-C, and 24% of patients continued to have multiple lipid abnormalities.10 Studies conducted in Europe have reported that the prevalence of multiple lipid abnormalities in patients primarily treated with statins is 30% to 40%.11,12 In contrast, few studies have investigated the attainment of multiple normal lipid levels in Asian patients treated with LMTs.
Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database
2010, AtherosclerosisCitation Excerpt :The substantial rates of elevated LDL-C and of abnormal HDL-C and/or TG levels despite statin therapy is consistent with results of smaller previous studies. A 73% rate of elevated LDL-C was reported in a recent cross-sectional observational study involving 946 patients treated with lipid-lowering agents, most often statins [13]. In that study, among individuals with elevated LDL-C, there was a 39% rate of abnormal HDL-C and/or TG levels.
Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs
2009, Archives of Cardiovascular Diseases